Hemogenyx Pharmaceuticals PLC Total Voting Rights (1786R)
February 28 2023 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 1786R
Hemogenyx Pharmaceuticals PLC
28 February 2023
28 February 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Total Voting Rights
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
announces that the total issued share capital of the Company as at
28 February 2022 consists of 1,141,999,321 ordinary shares of 1
pence each, none of which are held in treasury. Therefore, the
total number of voting rights in the Company is 1,141,999,321.
The figure of 1,141,999,321 ordinary shares may be used by
shareholders of the Company as the denominator for the calculations
by which they will determine if they are required to notify their
investment in, or a change in their interest in, the share capital
of the Company under the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREAAAXALXDEFA
(END) Dow Jones Newswires
February 28, 2023 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024